Invivogen
Menu

RANKL Reporter HEK 293 Cells

Product Unit size Cat. code Docs. Qty. Price

HEK-Blue™ RANKL Cells

Human & Mouse RANKL Reporter Cells

Show product

3-7 x 10e6 cells

hkb-rankl
+-
$1,457

HEK-Blue™ RANKL vial

Additional cell vial

Show product

3-7 x 10e6 cells

hkb-rankl-av
+-

Notification:  Reference #hkb-rankl-av can only be ordered together with reference #hkb-rankl.

RANKL Reporter Cells

Signaling pathways in HEK-Blue™ RANKL cells
Signaling pathways in HEK-Blue™ RANKL cells

HEK-Blue™ RANKL cells were engineered from the human embryonic kidney HEK293 cell line to detect bioactive human and murine RANKL (Receptor Activator of NF-κB Ligand) by monitoring the activation of the NF-κB and AP-1 pathways. In addition, these cells can be used for screening antibodies or small molecule inhibitors targeting the RANKL pathway.  
RANKL is a member of the TNF (Tumor Necrosis Factor) superfamily. This cytokine exists as a soluble or transmembrane protein produced by osteoblasts and activated T cells [1]. RANKL binding to its receptor RANK and the subsequent signaling events play a pivotal role in bone remodeling and dendritic cell survival, thereby enhancing the induction of T cell responses [1]. 

More details More details

 

Cell line description

HEK-Blue™ RANKL cells were generated by stable transfection with the gene encoding for human RANK (with all three functional TRAF-binding motifs) and an NF-κB/AP1-inducible secreted embryonic alkaline phosphatase (SEAP) reporter. The binding of RANKL to its receptor triggers a signaling cascade leading to the activation of NF-κB/AP1, and the subsequent production of SEAP. This can be readily assessed in the supernatant using QUANTI-Blue™ Solution, a SEAP detection reagent. 

HEK-Blue™ RANKL cells detect human (h) and murine (m) RANKL (see figures). Of note, these cells also respond to hIL-1β and, to a weaker extent, mIL-1β, as they endogenously express the IL-1β receptor. They are not responsive to human IFN-α, IFN-β, IFN-γ, and TNF-α (see figures).

Key features

  • Fully functional RANKL signaling pathway
  • Readily assessable NF-κB/AP1-inducible SEAP reporter activity
  • Strong response to human (h) and murine (m) RANKL
  • Response to hIL-1β and, to a weaker extent, mIL-1β
  • No response to hIFN-α, hIFN-β, hIFN-γ, and hTNF-α

Applications

  • Detection and quantification of human and murine RANKL activity
  • Screening of anti-RANKL and anti-RANK antibodies
  • Screening of small molecule inhibitors of the RANKL pathway

 

References:

1. Cheng ML. & Fong L.,  2014. Effects of RANKL-targeted therapy in immunity and cancer. Front. Oncol. 3:329.
2. Ahern E.et al., 2018. Roles of the RANKL-RANK axis in anti-tumour immunity — implications for therapy. Nat. Rev. Clin. Oncol. 15:676-93.
3. Nakai Y.et al., 2019. Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis. Bone Res. 7:1.

Figures

Evaluation of RANKL response in HEK-Blue™ RANKL Cells
Evaluation of RANKL response in HEK-Blue™ RANKL Cells

Dose-response of HEK-Blue™ RANKL cells to recombinant RANKL.

Cells were stimulated with increasing concentrations of recombinant human or murine RANKL. After overnight incubation, the NF-κB response was determined using QUANTI‑Blue™ Solution, a SEAP detection reagent, and reading the optical density (OD) at 630 nm. EC50 values are shown as mean ± SD.

HEK-Blue™ RANKL specificity
HEK-Blue™ RANKL specificity

HEK-Blue™ RANKL cell responses to cytokines. Cells were stimulated with 10 ng/ml of hRANKL, mRANKL, hIL‑1β, mIL‑1β, 1x104 IU/ml of hIFN-α, hIFN-β, 100 ng/ml of hIFN-γ, or hTNF-α. After overnight incubation, SEAP activity was assessed using QUANTI‑Blue™ Solution. The optical density (OD) at 630 nm is shown as mean ± SEM.

Dose-dependent neutralization of RANK/RANKL signaling
Dose-dependent neutralization of RANK/RANKL signaling

Dose-dependent inhibition of HEK‑Blue™ RANKL cellular response using a neutralizing antibody against human RANKL. An increasing concentration of a neutralizing anti-hRANKL antibody was incubated with recombinant human RANKL for 2 hours before the addition of HEK-Blue™ RANKL cells. After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™. Data are shown as a percentage (%) inhibition of reporter activity without anti-hRANKL antibody.

Back to the top

Specifications

Antibiotic resistance: Blasticidin,  Zeocin®

Growth medium: DMEM, 4.5 g/l glucose, 2-4 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml Normocin™

Guaranteed mycoplasma-free

Specificity: human and mouse RANKL

Detection range:

  • 3 - 100 ng/ml for human RANKL
  • 1 - 100 ng/ml for murine RANKL

 

These cells are covered by a Limited Use License (See Terms and Conditions).

Back to the top

Contents

Dry Ice Shipped on dry ice (Europe, USA, Canada and some areas in Asia)

Back to the top

Details

Receptor Activator of NF-κB Ligand (RANKL), also known as member 11 of the tumor necrosis factor (TNF) superfamily (TNFSF11) or TNF-related activation-induced cytokine (TRANCE), exists as a transmembrane or soluble protein produced by osteoblasts and activated T cells [1]. RANKL binds to its receptor RANK via an obligate trimer configuration [1, 2].
RANKL/RANK signaling plays a pivotal role in bone remodeling and dendritic cell survival, thereby enhancing the induction of T cell responses [1]. Upon RANKL binding, RANK trimers recruit TNF receptor-associated factor (TRAF) adaptor proteins, such as TRAF6, to TRAF-binding motifs within their cytoplasmic domains [1].
The TRAF6 signaling cascade results in the activation of NF-κB and AP-1 transcription factors. Multiple efforts have focused on the development of anti‑RANKL antibodies or small‑molecule inhibitors for blocking RANKL/RANK signaling to reduce osteoporosis, prevent skeletal-related events (SREs) from bone metastasis in cancer, or improve anti-tumor immunity [1-3].

 

1. Cheng ML. & Fong L., 2014. Effects of RANKL-targeted therapy in immunity and cancer. Front. Oncol. 3:329.
2. Ahern E. et al., 2018. Roles of the RANKL-RANK axis in anti-tumour immunity — implications for therapy. Nat. Rev. Clin. Oncol. 15:676-93.
3. Nakai Y. et al., 2019. Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis. Bone Res. 7:1.

Back to the top

FAQ Cell Lines

Visit our FAQ Any questions about our cell lines ? Visit our frequently asked questions page

Back to the top

Notification:  This product is for internal research use only. Additional rights may be available. Please visit InvivoGen’s Terms and Conditions.

Customer Service
& Technical Support
Shopping cart is empty